PREVENTS FATTY LIVER AND LIVER DISEASES
Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease, with a worldwide prevalence of 25%. In the United States, NAFLD and its subtype, nonalcoholic steatohepatitis, affect 30% and 5% of the population, respectively. Considering the ongoing obesity epidemic beginning in childhood, the rise in diabetes, and other factors, the prevalence of NAFLD along with the proportion of those with advanced liver disease is projected to continue to increase.
Mice are fed high fat diets and given intraperitoneal injections of Insumate® for 8 weeks. The livers of these mice were extracted for analysis to find that Insumate® could effectively reduce the accumulation of liver fat and reduce the amount of peroxides in the liver.